Literature DB >> 19429035

Association analysis between polymorphisms in the conserved dopamine neurotrophic factor (CDNF) gene and cocaine dependence.

Falk W Lohoff1, Paul J Bloch, Thomas N Ferraro, Wade H Berrettini, Helen M Pettinati, Charles A Dackis, Charles P O'Brien, Kyle M Kampman, David W Oslin.   

Abstract

Cocaine-induced neuroplasticity changes in the mesocorticolimbic dopamine systems are thought to be involved in the pathophysiology of cocaine dependence. Since neurotrophic factors have been observed to prevent/reverse and mimic cocaine-induced neurobiological changes in the brain, related genes are plausible candidates for susceptibility to cocaine dependence. The novel conserved dopamine neurotrophic factor protein (CDNF) promotes the survival, growth, and function of dopamine-specific neurons and is expressed in brain regions that undergo cocaine-induced neuroplasticity. In this study, we hypothesize that polymorphisms in the CDNF gene (CDNF/ARMETL1) contribute to increased risk for cocaine dependence. Cocaine dependent individuals (n=351) and unaffected controls (n=257) of African descent were genotyped for four single nucleotide polymorphisms (SNPs) in the CDNF gene (rs11259365, rs7094179, rs7900873, rs2278871). We observed no significant differences in allele, genotype, or haplotype frequencies between cases and controls for any of the tested SNPs. Our study suggests that there is no association between variants in the CDNF gene and cocaine dependence. However, additional studies using larger sample sizes, comprehensive SNP coverage, and clinically homogenous populations are necessary before confidently excluding CDNF as a significant genetic risk factor for cocaine dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429035      PMCID: PMC2680755          DOI: 10.1016/j.neulet.2009.02.026

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  54 in total

1.  Genomic control for association studies.

Authors:  B Devlin; K Roeder
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

Review 2.  Brain circuitry and the reinstatement of cocaine-seeking behavior.

Authors:  Peter W Kalivas; Krista McFarland
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

3.  Linkage analysis of a complex disease through use of admixed populations.

Authors:  Xiaofeng Zhu; Richard S Cooper; Robert C Elston
Journal:  Am J Hum Genet       Date:  2004-05-06       Impact factor: 11.025

4.  Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents?

Authors:  Nicolas Ballon; Sophie Leroy; Christianne Roy; Marie-Chantal Bourdel; Jean-Pierre Olie; Aimé Charles-Nicolas; Marie-Odile Krebs; Marie-France Poirier
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-12-05       Impact factor: 3.568

Review 5.  The TDT and other family-based tests for linkage disequilibrium and association.

Authors:  R S Spielman; W J Ewens
Journal:  Am J Hum Genet       Date:  1996-11       Impact factor: 11.025

6.  Dopamine transporter gene polymorphisms are not associated with polysubstance abuse.

Authors:  A M Persico; D J Vandenbergh; S S Smith; G R Uhl
Journal:  Biol Psychiatry       Date:  1993-08-15       Impact factor: 13.382

7.  A heteromeric protein that binds to a meiotic homologous recombination hot spot: correlation of binding and hot spot activity.

Authors:  W P Wahls; G R Smith
Journal:  Genes Dev       Date:  1994-07-15       Impact factor: 11.361

8.  Genetic and environmental contributions to nicotine, alcohol and cannabis dependence in male twins.

Authors:  Hong Xian; Jeffrey F Scherrer; Julia D Grant; Seth A Eisen; William R True; Theodore Jacob; Kathleen K Bucholz
Journal:  Addiction       Date:  2008-08       Impact factor: 6.526

9.  Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence.

Authors:  Falk W Lohoff; Andrew E Weller; Paul J Bloch; Aleksandra H Nall; Thomas N Ferraro; Kyle M Kampman; Helen M Pettinati; David W Oslin; Charles A Dackis; Charles P O'Brien; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

10.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

Authors:  Päivi Lindholm; Merja H Voutilainen; Juha Laurén; Johan Peränen; Veli-Matti Leppänen; Jaan-Olle Andressoo; Maria Lindahl; Sanna Janhunen; Nisse Kalkkinen; Tõnis Timmusk; Raimo K Tuominen; Mart Saarma
Journal:  Nature       Date:  2007-07-05       Impact factor: 49.962

View more
  1 in total

Review 1.  Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.

Authors:  Tingting Tang; Yong Li; Qian Jiao; Xixun Du; Hong Jiang
Journal:  Neurosci Bull       Date:  2017-03-23       Impact factor: 5.203

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.